TPBG/5T4: the Oncofetal Protein, an Appealing Target for ADC or Vaccine Therapeutics in Tumors!
|
TPBG/5T4: the Oncofetal Protein, an Appealing Target for ADC or Vaccine Therapeutics in Tumors! Trophoblast glycoprotein (TPBG, also termed as 5T4 or WAIF1) is a glycoprotein found in embryonic trophoblast cells. Abundant evidence indicated that TPBG is closely associated with different physiological processes, like intercellular junctions, cell morphology and motility, cell adhesion capacity etc. Intriguingly, successive studies have uncovered that TPBG is highly expressed in a variety of solid tumors. Therefore, it is considered as a tumor-associated antigen and becomes an up-coming target for anti-cancer drugs design (Click to Read More about TPBG). ClinicalTrial noted over 10 TPBG-targeted drugs in clinical development. Oxford BioMedica's TroVax, an MVA-based vaccine targeting TPBG has been evaluated in clinical trials in various tumors, demonstrating that patients given TroVax show "significant anti-5T4 immune responses". In addition, Asana BioSciences' ASN004, a novel TPBG-targeted Dolaflexin™ ADC, the results from ASN004 preclinical works indicated that ASN004 achieves complete regressions and tumor-free survivors in solid tumor models (TPBG Clinical Trials for Drug Development). To assist researchers or pharmaceutical companies in their research on TPBG in tumors or other diseases, CUSABIO presents TPBG active protein products to support your research on the mechanism of TPBG or its potential clinical value (click for the full list of TPBG products: TPBG Proteins; TPBG antibodies). |
|||||||||||||||||||||||||||||||||||||||||||||
|
